Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice
- 22 April 2005
- journal article
- Published by Springer Nature in Cell and tissue research
- Vol. 320 (3) , 509-515
- https://doi.org/10.1007/s00441-005-1102-z
Abstract
Dramatic clinical success in the treatment of chronic inflammatory diseases has resulted from the use of anti-cytokine therapies including specific blocking antibodies, soluble receptors and traps to silence the actions of inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Two agents used clinically to block the functional activity of TNFα protein are Remicade (an antibody) and Enbrel (a soluble TNF receptor). These tools are now being extended to many other clinical disorders. We have a specific interest in the treatment of muscle diseases. In order to study the effects of novel anti-cytokine drugs on mouse models of human disease, such drugs must be investigated to determine whether they are indeed effective in blocking the inflammatory response in mouse. This has been carried out by means of a simple in vivo bioassay. Histological examination of transverse sections from whole muscle autografts in C57BL/10ScSn mice sampled at 5 days after transplantation provides an excellent assay model and clearly shows that Remicade and Enbrel block the acute inflammatory cell response in vivo. This graft model has also been used to show that a single intraperitoneal injection of Remicade (10 μg/g) is long-lived and effective when administered at 1 week and even 4 weeks prior to the assay. Enbrel is highly effective when injected twice at −3 days and −1 day (2×100 μg) before muscle grafting but shows no inhibition of the inflammatory response after a single injection (100 μg) 1 week prior to grafting. This striking ablation of inflammation by pharmacological blockage of TNFα is in marked contrast to the lack of any effect in TNFα null mice. This simple reproducible in vivo assay model in mice can be used to evaluate the efficacy of many novel anti-cytokine interventions designed to block inflammation.Keywords
This publication has 25 references indexed in Scilit:
- Crohn's disease: future anti–tumor necrosis factor therapies beyond infliximabGastroenterology Clinics of North America, 2004
- Anti–tumor necrosis factor α therapy and heart failure: What have we learned and where do we go from here?Arthritis & Rheumatism, 2004
- Inflammatory mediators in chronic heart failure: an overviewHeart, 2004
- Anti‐TNFα (Remicade®) therapy protects dystrophic skeletal muscle from necrosisThe FASEB Journal, 2004
- New strategies to control inflammatory synovitis: interleukin 15 and beyondAnnals of the Rheumatic Diseases, 2003
- Defective membrane repair in dysferlin-deficient muscular dystrophyNature, 2003
- Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trialArthritis & Rheumatism, 2003
- New Concepts in the Treatment of Rheumatoid ArthritisAnnual Review of Medicine, 2003
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- Potential of anticytokine therapies in central nervous system ischaemiaExpert Opinion on Biological Therapy, 2001